Clinical Trial: A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured From the 2003 Measles Stock Seed With Recombinant Human Albumin (rHA) Versus Currently L
Brief Summary: The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human albumin).
Detailed Summary: The duration of treatment is 6 weeks.
Sponsor: Merck Sharp & Dohme Corp.
Current Primary Outcome: Antibody response rate to measles at 6 weeks postvaccination
Original Primary Outcome:
Current Secondary Outcome: Geometric mean titers to measles by ELISA at 6 weeks postvaccination
Original Secondary Outcome:
Information By: Merck Sharp & Dohme Corp.
Dates:
Date Received: April 26, 2005
Date Started: October 2004
Date Completion:
Last Updated: March 14, 2017
Last Verified: March 2017